DDInter397 DDInter1544
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Clidinium {u} (Compound) resembles {v} (Compound) Diphenylpyraline
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Clidinium {u} (Compound) binds {v} (Gene) CHRM3
Clidinium {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Antagonists
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bendroflumethiazide
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrochlorothiazide
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Clidinium {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Clidinium {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Clidinium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darifenacin
Clidinium (Compound) resembles Diphenylpyraline (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Clidinium (Compound) binds CHRM3 (Gene)
Clidinium (Compound) is included by Cholinergic Antagonists (Pharmacologic Class)
Clidinium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide
Clidinium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Clidinium may lead to a major life threatening interaction when taken with Potassium chloride
Clidinium may lead to a major life threatening interaction when taken with Zonisamide
Clidinium (Compound) resembles Darifenacin (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin